Trial Profile
A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Alisertib (Primary) ; Sapanisertib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer; Uterine cancer
- Focus Adverse reactions
- 07 Jun 2022 final results (n=31) from the dose expansion portion of this clinical trial, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 10 Jun 2021 Status changed from active, no longer recruiting to completed.
- 05 Mar 2021 Planned End Date changed from 1 Nov 2021 to 1 Nov 2023.